Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine As Add-on Treatment for Multiple Sclerosis RedNova Wed, 24 Jan 2007 3:24 AM PST GENEVA, Switzerland, January 24 /PRNewswire-FirstCall/ -- Merck Serono (virt-x: SERO and NYSE: SRA) announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.

Health & Beauty Belfast Telegraph Wed, 24 Jan 2007 3:36 AM PST The Tory leader, who has refused to answer media questions about whether he used drugs before entering politics, ruled out a wider legalisation of cannabis for recreational use.

Michael J. Fox Foundation Funds Allon to Evaluate AL-108 for Parkinson’s Disease
T-Net British Columbia Wed, 24 Jan 2007 8:48 AM PST
Vancouver, BC, January 24, 2007--(T-Net)--Allon Therapeutics (TSX:NPC), The Neuro Protection Company, today announced it has received funding from The Michael J. Fox Foundation for Parkinson’s Research to evaluate the effectiveness of Allon’s lead drug AL-108 in pre-clinical models of Parkinson’s disease.

Expanding Phase IV Trials and Use of Biomarkers for Personalized ...
Pharmaceutical Processing - Rockaway,NJ,USA
Just this past February, sales of the multiple sclerosis drug Tysabri were suspended after it was suspected of triggering a rare brain disease in three ...


http://tinyurl.com/2gxetj